Structure Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

GPCR$21.73+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity

(IN THOUSANDS)



· · · · · · · · · · ACCUMULATED · · · · · ·
· · ORDINARY · · ADDITIONAL · · OTHER · · · · · TOTAL
· · SHARES · · PAID-IN · · COMPREHENSIVE · · ACCUMULATED · · SHAREHOLDERS’
· · SHARES · · AMOUNT · · CAPITAL · · INCOME (LOSS) · · DEFICIT · · EQUITY
Balance at December 31, 2025	212,513	$21	$1,985,602	$1,054	$(470,300)	$1,516,377
Issuance of ordinary shares upon exercise of vested share options	231	—	869	—	—	869
Issuance of ordinary shares upon vesting of restricted share units	586	—	—	—	—	—
Shares withheld for taxes	(122)	—	(2,574)	—	—	(2,574)
Share-based compensation expense	—	—	11,639	—	—	11,639
Unrealized loss on investments, net	—	—	—	(3,249)	—	(3,249)
Net loss	—	—	—	—	(75,968)	(75,968)
Balance at March 31, 2026	213,208	21	1,995,536	(2,195)	(546,268)	1,447,094
Issuance of ordinary shares upon exercise of vested share options	280	—	1,213	—	—	1,213
Issuance of ordinary shares pursuant to employee share purchase plan	114	—	872	—	—	872
Issuance of ordinary shares upon vesting of restricted share units	53	—	—	—	—	—
Share-based compensation expense	—	—	12,634	—	—	12,634
Unrealized loss on investments, net	—	—	—	(1,250)	—	(1,250)
Net loss	—	—	—	—	(106,159)	(106,159)
Balance at June 30, 2026	213,655	$21	$2,010,255	$(3,445)	$(652,427)	$1,354,404



· · · · · · · · · · ACCUMULATED · · · · · ·
· · ORDINARY · · ADDITIONAL · · OTHER · · · · · TOTAL
· · SHARES · · PAID-IN · · COMPREHENSIVE · · ACCUMULATED · · SHAREHOLDERS’
· · SHARES · · AMOUNT · · CAPITAL · · INCOME (LOSS) · · DEFICIT · · EQUITY
Balance at December 31, 2024	171,860	$17	$1,193,010	$914	$(329,098)	$864,843
Issuance of ordinary shares upon exercise of vested share options	644	—	965	—	—	965
Issuance of ordinary shares upon vesting of restricted share units	134	—	—	—	—	—
Shares withheld for taxes	(28)	—	(156)	—	—	(156)
Share-based compensation expense	—	—	5,918	—	—	5,918
Unrealized loss on investments, net	—	—	—	(99)	—	(99)
Net loss	—	—	—	—	(46,833)	(46,833)
Balance at March 31, 2025	172,610	17	1,199,737	815	(375,931)	824,638
Issuance of ordinary shares upon exercise of vested share options	22	—	43	—	—	43
Issuance of ordinary shares pursuant to employee share purchase plan	68	—	474	—	—	474
Depository issuance cost offset	—	—	1,531	—	—	1,531
Share-based compensation expense	—	—	7,509	—	—	7,509
Unrealized loss on investments, net	—	—	—	(453)	—	(453)
Net loss	—	—	—	—	(61,661)	(61,661)
Balance at June 30, 2025	172,700	$17	$1,209,294	$362	$(437,592)	$772,081

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.